Dr. Eugene Pashkovetsky, MD

Dr. Pashkovetsky practices at Capital Cardiology Associates in Albany, New York.

Dr. Pashkovetsky's NPI, 1588930770, was assigned on April 1, 2012. Dr. Pashkovetsky graduated from St. George's University School of Medicine in 2012. Dr. Pashkovetsky holds New York license 281254.

Dr. Pashkovetsky's primary practice is Capital Cardiology Associates, at 7 Southwoods Blvd, Albany, NY 12211 in Albany County. The practice phone is (518) 292-6000.

Dr. Pashkovetsky's primary practice is Capital Cardiology Associates in Albany, New York. Dr. Pashkovetsky is also affiliated with Albany Medical Center. The medical group on file is Capital Cardiology Associates. Dmand AI also links Dr. Pashkovetsky to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pashkovetsky practices, 6 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Pashkovetsky's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Pashkovetsky is licensed in New York.

CMS data shows 6,972 Medicare services from Dr. Pashkovetsky across 54 procedure codes in 2024, for 1,543 Medicare patients. Medicare paid $531,001 for them.

CMS counts 1,543 Medicare patients who saw Dr. Pashkovetsky in 2024. The largest group is 65 to 74, with 588 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pashkovetsky's median patient age at 67, with 47% women.

In 2024, Dr. Pashkovetsky wrote 4,400 Medicare Part D claims for 720 patients. 73% of them were for generic drugs. CMS names the drug for 4,132 of them, across 52 drugs with 11 or more claims each, at $4,936,469 in total drug cost. In 2023, CMS named 2,751 claims across 43 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Pashkovetsky for performance year 2024, reported individually. Dr. Pashkovetsky accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Pashkovetsky, published from 2019 to 2021. 2019 was the busiest year, with 2. The most frequent topics are Immunosuppressive Agents, Kidney Transplantation and Pericardial Effusion. Dr. Pashkovetsky has published most often in Transplant Proc. Dr. Pashkovetsky's most frequent co-authors are Nikolaos Chandolias, MD, Reynold Ivan Lopez-Soler, MD, PhD and Stephani C. Wang.

Dmand AI links Dr. Pashkovetsky to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Mitral Valve Insufficiency and Heart Valve Diseases.

CMS Open Payments shows 671 general payments to Dr. Pashkovetsky from 37 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 47% of the total. Bristol-Myers Squibb Company paid the most, $13,177.

Dr. Pashkovetsky graduated from St. George's University School of Medicine in 2012.